 |
Business Wire - December 15, 2003
In the recent Strategic Focus Report on Retractable Syringes Market Outlook, Frost & Sullivan found that Retractable Technologies' safety needle devices are bringing increased safety to the healthcare industry. VanishPoint(R) virtually eliminates the risk of transmission of potentially deadly bloodborne diseases, such as HIV/AIDS and hepatitis C, through exposure to contaminated needles. Such transmission can occur through accidental needlestick injuries among healthcare workers, needle reuse, and needle sharing. In the U. S. alone, an estimated 800,000 accidental needlestick injuries are reported each year.
"We're proud to present this award to Retractable for its life-saving VanishPoint(R) products," said Dorman Followwill, vice president of Global Healthcare, for Frost & Sullivan. Amit Bohora, Frost & Sullivan industry analyst, added, "VanishPoint(R) devices are clearly the gold standard in retractable syringes."
Frost & Sullivan found that the VanishPoint(R) product line represents a major improvement over other retractable syringes currently on the market. Once the injection is complete, the needle automatically retracts from the patient into the barrel of the device. As a result, the healthcare provider is not exposed to potentially life-threatening needlestick injuries. In addition, the syringe cannot be reused, a feature that is especially important in Africa and elsewhere in the developing world, where needle reuse is a major cause of transmission of HIV/AIDS and other infectious diseases.
Frost & Sullivan also pointed out that VanishPoint(R) devices are highly cost-effective for two key reasons. Not only are they one of the safest needle devices on the market, but they are also the least expensive to manufacture. Because they virtually eliminate the risk of accidental needlestick injuries, they also virtually eliminate the need for the expensive testing and treatment of healthcare workers that may be necessary after such injuries.
Frost and Sullivan chose Retractable after conducting interviews with market participants and performing extensive research using proprietary data. The firm also ranked the finalists based on quality control in product manufacturing. Retractable Technologies garnered the number one ranking by demonstrating that it understands that quality control is an essential element of satisfying customers, increasing repeat buying behavior, and assuring long-term market survival.
About Retractable Technologies
Little Elm, Texas-based Retractable Technologies Inc. designs, develops, manufactures and markets safety-needle devices for the healthcare industry. The Company's VanishPoint(R) products, which utilize a patented friction ring mechanism, are designed specifically to prevent accidental needlestick injuries and needle reuse. For more information, visit www.vanishpoint.com.
About Frost & Sullivan
Founded in 1961, Frost & Sullivan is recognized as a global leader in growth consulting. Frost & Sullivan Awards are presented to companies that demonstrate excellence in their industry, commending the diligence, commitment, and innovative business strategies required to advance in the global marketplace. Frost & Sullivan rigorously analyzes specific criteria to determine award recipients in a vast variety of market industries and landscapes. For further information, visit www.frost.com.
CONTACT: Frost & Sullivan, San Antonio
Jamie Frizzell, 210-247-2496, jfrizzell@frost.com
SOURCE: Frost & Sullivan
031215
BW031204
Copyright © 2003 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .